University of Texas Southwestern Medical Center
utsouthwestern.eduTotal trials
982
Active
231
Phase 3
43
Total enrollment
915,473
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 105 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Potassium citrate | — | — | — | — | 2 | ||
| Ergocalciferol | — | — | — | — | — | 2 | |
| Semaglutide | — | — | — | — | — | 1 | |
| clozapine | — | — | — | — | — | 1 | |
| risperidone | — | — | — | — | — | 1 | |
| Cladribine | — | — | — | — | — | 1 | |
| Calcium Citrate with Vitamin D2 | — | — | — | — | — | 1 | |
| Deucravacitinib | — | — | — | — | — | 1 | |
| Tafamidis 61 MG | — | — | — | — | — | 1 | |
| Denosumab | — | — | — | — | — | 1 | |
| EffCaMgCit | — | — | — | — | — | 3 | |
| Gemcitabine | — | — | — | 3 | |||
| Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor | — | — | — | — | — | 1 | |
| Weight loss | — | — | — | — | — | 1 | |
| Admixture of propofol and etomidate at a ratio by volume of 75%/25% | — | — | — | — | — | 1 | |
| Admixture of propofol and etomidate at a ratio by volume of 25%/75% | — | — | — | — | — | 1 | |
| Curcumin | — | — | — | — | — | 1 | |
| Tofacitinib 10mg | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 3 | |
| Ketamine Hydrochloride | — | — | 5 | ||||
| Polypill | — | — | — | — | — | 4 | |
| Cadonilimab | — | — | — | — | 2 | ||
| Atezolizumab | — | — | — | — | — | 2 | |
| Escitalopram | — | — | — | 4 | |||
| Midazolam Hydrochloride | — | — | — | — | 2 | ||
| Nivolumab | — | — | — | — | — | 4 | |
| paclitaxel | — | — | — | — | — | 4 | |
| Orlistat | — | — | — | — | — | 3 | |
| Bevacizumab | — | — | — | — | 3 | ||
| Abemaciclib | — | — | — | — | 2 | ||
| Letrozole | — | — | — | — | — | 2 | |
| Ipilimumab | — | — | — | — | — | 2 | |
| Enfortumab vedotin | — | — | — | — | — | 1 | |
| Combined prescription of the individual medications | — | — | — | — | — | 1 | |
| Belantamab mafodotin 2.5 mg/kg | — | — | — | — | — | 1 | |
| Belantamab mafodotin 1.9 mg/kg | — | — | — | — | — | 1 | |
| Belantamab mafodotin 1.4 mg/kg | — | — | — | — | — | 1 | |
| Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages | — | — | — | — | — | 1 | |
| Belantamab mafodotin 1.0 mg/kg | — | — | — | — | — | 1 | |
| Mitoquinone/mitoquinol mesylate | — | — | — | — | — | 1 |
65 more active programs hidden
Next readouts
- 2024-11-08
- 2025-06-16
- 2025-12-31
- 2026-02
- 2026-03-31
- 2026-04-15
- 2026-04-20
- 2026-05-01
- 2026-06
- 2026-06-30
Top conditions
- Hypertension25
- Depression25
- Breast Cancer22
- Obesity19
- Bipolar Disorder17
- Major Depressive Disorder16
- Prostate Cancer13
- Heart Failure13
Frequently asked questions about University of Texas Southwestern Medical Center
- How many clinical trials does University of Texas Southwestern Medical Center have on ClinicalTrials.gov?
- University of Texas Southwestern Medical Center is listed as the lead sponsor on 982 clinical trials in ClinicalTrials.gov, 231 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Texas Southwestern Medical Center's trials are in Phase 3?
- 43 of University of Texas Southwestern Medical Center's trials are in Phase 3, spread across 105 active drug programs.
- What therapeutic areas does University of Texas Southwestern Medical Center focus on?
- University of Texas Southwestern Medical Center's most-studied conditions on ClinicalTrials.gov are Hypertension, Depression, Breast Cancer, Obesity, Bipolar Disorder.
- When are University of Texas Southwestern Medical Center's next clinical trial readouts?
- University of Texas Southwestern Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]”, expected around 2024-11-08.